The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome are collaborating on a $50 million effort to boost ...

Nebraska conducts CWD surveillance in four to seven regions each year, rotating to a different part of the state each season.

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESS Newswire / February 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based det ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

A study reveals alarming rates of antibiotic resistance in Gram-negative bacteria, highlighting the urgent need for ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Measles was one of the deadliest infectious diseases for children prior to 1915. But in just two decades from 1915 in the UK, ...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...